Cardiomyopathy-Pipeline Review, H1 2015

Cardiomyopathy-Pipeline Review, H1 2015

  • Products Id :- GMDHC6263IDB
  • |
  • Pages: 113
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cardiomyopathy-Pipeline Review, H1 2015


Global Markets Direct's, 'Cardiomyopathy-Pipeline Review, H1 2015', provides an overview of the Cardiomyopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Cardiomyopathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cardiomyopathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cardiomyopathy Overview 9

Therapeutics Development 10

Pipeline Products for Cardiomyopathy-Overview 10

Pipeline Products for Cardiomyopathy-Comparative Analysis 11

Cardiomyopathy-Therapeutics under Development by Companies 12

Cardiomyopathy-Therapeutics under Investigation by Universities/Institutes 14

Cardiomyopathy-Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Cardiomyopathy-Products under Development by Companies 18

Cardiomyopathy-Products under Investigation by Universities/Institutes 20

Cardiomyopathy-Companies Involved in Therapeutics Development 21

Array BioPharma Inc. 21

Beech Tree Labs, Inc. 22

Bioheart, Inc. 23

Celladon Corporation 24

Gilead Sciences, Inc. 25

Kasiak Research Pvt. Ltd. 26

LG Life Sciences, Ltd. 27

miRagen Therapeutics, Inc. 28

MyoKardia, Inc. 29

Neurimmune Holding AG 30

Novartis AG 31

Nyken BV 32

Sanofi 33

Shire Plc 34

Stemedica Cell Technologies, Inc. 35

Stempeutics Research Private Limited 36

Torrent Pharmaceuticals Limited 37

Vericel Corporation 38

Cardiomyopathy-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Target 40

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

AdipoCell-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

ARRY-797-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

binimetinib-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

CAP-1002-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Cyndacel-M-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Drug for Cardiomyopathy-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Drugs to Activate Nrf2 for Diabetic Cardiomyopathy-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Gene Therapy for Cardiomyopathy-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Gene therapy to Activate mSCF for Ischemic Cardiomyopathy-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

GLP-1-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

GS-6615-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

ixmyelocel-T-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

JR-100-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

LC-280126-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Mesenchymal Stem Cells-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

MGN-9103-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Monoclonal Antibodies for Cardiovascular Diseases-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

MYK-461-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

NI-301-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

NYK-1112-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

perhexiline maleate-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Refacell-DCM-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

SHP-627-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecule for Dilated Cardiomyopathy-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Stempeucel-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

TRC-120038-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Cardiomyopathy-Recent Pipeline Updates 88

Cardiomyopathy-Dormant Projects 105

Cardiomyopathy-Product Development Milestones 106

Featured News & Press Releases 106

Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T 106

Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell's Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy 106

Nov 12, 2014: Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan 107

Oct 27, 2014: Celladon Corporation Announces Publication of Data From Its Stem Cell Factor Gene Therapy Program in Circulation Heart Failure 107

Aug 22, 2014: Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy 108

Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell's itMSC Therapy to Treat Dilated Chronic Heart Failure 109

Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 110

Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 110

Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada 111

Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 111

Appendix 112

Methodology 112

Coverage 112

Secondary Research 112

Primary Research 112

Expert Panel Validation 112

Contact Us 112

Disclaimer 113

List of Tables

Number of Products under Development for Cardiomyopathy, H1 2015 10

Number of Products under Development for Cardiomyopathy-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Comparative Analysis by Unknown Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Cardiomyopathy-Pipeline by Array BioPharma Inc., H1 2015 21

Cardiomyopathy-Pipeline by Beech Tree Labs, Inc., H1 2015 22

Cardiomyopathy-Pipeline by Bioheart, Inc., H1 2015 23

Cardiomyopathy-Pipeline by Celladon Corporation, H1 2015 24

Cardiomyopathy-Pipeline by Gilead Sciences, Inc., H1 2015 25

Cardiomyopathy-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 26

Cardiomyopathy-Pipeline by LG Life Sciences, Ltd., H1 2015 27

Cardiomyopathy-Pipeline by miRagen Therapeutics, Inc., H1 2015 28

Cardiomyopathy-Pipeline by MyoKardia, Inc., H1 2015 29

Cardiomyopathy-Pipeline by Neurimmune Holding AG, H1 2015 30

Cardiomyopathy-Pipeline by Novartis AG, H1 2015 31

Cardiomyopathy-Pipeline by Nyken BV, H1 2015 32

Cardiomyopathy-Pipeline by Sanofi, H1 2015 33

Cardiomyopathy-Pipeline by Shire Plc, H1 2015 34

Cardiomyopathy-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 35

Cardiomyopathy-Pipeline by Stempeutics Research Private Limited, H1 2015 36

Cardiomyopathy-Pipeline by Torrent Pharmaceuticals Limited, H1 2015 37

Cardiomyopathy-Pipeline by Vericel Corporation, H1 2015 38

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Stage and Target, H1 2015 40

Number of Products by Stage and Mechanism of Action, H1 2015 42

Number of Products by Stage and Route of Administration, H1 2015 44

Number of Products by Stage and Molecule Type, H1 2015 46

Cardiomyopathy Therapeutics-Recent Pipeline Updates, H1 2015 88

Cardiomyopathy-Dormant Projects, H1 2015 105

List of Figures

Number of Products under Development for Cardiomyopathy, H1 2015 10

Number of Products under Development for Cardiomyopathy-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Stage and Top 10 Targets, H1 2015 40

Number of Products by Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Top 10 Routes of Administration, H1 2015 43

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 44

Number of Products by Top 10 Molecule Types, H1 2015 45

Number of Products by Stage and Top 10 Molecule Types, H1 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Array BioPharma Inc.

Beech Tree Labs, Inc.

Bioheart, Inc.

Celladon Corporation

Gilead Sciences, Inc.

Kasiak Research Pvt. Ltd.

LG Life Sciences, Ltd.

miRagen Therapeutics, Inc.

MyoKardia, Inc.

Neurimmune Holding AG

Novartis AG

Nyken BV


Shire Plc

Stemedica Cell Technologies, Inc.

Stempeutics Research Private Limited

Torrent Pharmaceuticals Limited

Vericel Corporation

Cardiomyopathy Therapeutic Products under Development, Key Players in Cardiomyopathy Therapeutics, Cardiomyopathy Pipeline Overview, Cardiomyopathy Pipeline, Cardiomyopathy Pipeline Assessment

select a license

Single User License
USD 2000 INR 136140
Site License
USD 4000 INR 272280
Corporate User License
USD 6000 INR 408420



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]